DMD and Duchenne muscular dystrophy: Moving forward, it will be increasingly important to develop BMD therapeutics because the goal of many DMD therapeutics is to convert a severe DMD genotype (dystrophin-null) into a milder BMD-like phenotype (in-frame, reduced dystrophin) through exon skipping or gene therapies.